Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/19761
Title: International Atomic Energy Agency-Sponsored Multination Study of Intra-Arterial Rhenium-188-Labeled Lipiodol in the Treatment of Inoperable Hepatocellular Carcinoma: Results With Special Emphasis on Prognostic Value of Dosimetric Study
Authors: Patricia Bernal
Jean Luc Raoul
Janez Stare
Erdenechimeg Sereegotov
Felix X. Sundram
Ajay Kumar
Jae Min Jeong
Pawana Pusuwan
Chaitanya Divgi
Pat Zanzonico
Gaj Vidmar
John Buscombe
Trinh Thi Minh Chau
Maung Maung Saw
Shaoliang Chen
Ruben Ogbac
Maurizio Dondi
Ajit Kumar Padhy
Fundacion Santa Fe de Bogota
Centre Régional de Lutte contre le Cancer
University of Ljubljana Faculty of Medicine
Mongolian National University of Medical Sciences
Singapore General Hospital
All India Institute of Medical Sciences, New Delhi
Seoul National University Hospital
Mahidol University
Memorial Sloan-Kettering Cancer Center
UCL
Cho Ray Hospital
Fudan University
St. Luke's Medical Centre
International Atomic Energy Agency, Vienna
Keywords: Medicine
Issue Date: 1-Mar-2008
Citation: Seminars in Nuclear Medicine. Vol.38, No.2 (2008)
Abstract: A multicenter study was sponsored by the International Atomic Energy Agency (IAEA) to assess the safety and efficacy of transarterial rhenium-188 (188Re) HDD lipiodol (radioconjugate to lipiodol using an HDD kit) in the treatment of unresectable hepatocellular carcinoma. During 5 years, 185 patients received at least 1 treatment of radioconjugate, and 51 were retreated. The level of radioconjugate administered was based on radiation-absorbed dose to critical normal organs, calculated after a "scout" dose of radioconjugate. The total injected activity, including the scout dose during the first treatment, ranged from 21 to 364 mCi (mean, 108 mCi/4 GBq). Immediate and late side-effects were minimal. Tumor size could be evaluated in 88 patients. Among these patients, the objective response rate was 25%; stable disease was observed in 53% and tumor progression in 22%. With a median follow-up of 455 days, the estimated 12- and 24-month overall survival was 46% and 23%. This multicenter study shows that188Re lipiodol is a safe and cost-effective method to treat primary hepatocellular carcinoma via the transarterial route and requires further evaluation by treatment of greater numbers of patients. © 2008 Elsevier Inc. All rights reserved.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=38549173323&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/19761
ISSN: 00012998
Appears in Collections:Scopus 2006-2010

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.